Maruho Report 2023

14/60

Maruho Report 20231389,17189,17188,95488,95496,75496,75413.813.912,34712,34712,33312,3332019202095,39095,39096,18496,18422.717.221,94221,94216,43116,431202120222023Net sales / Operating profit / Ratio of operating profit to net sales2. Value Creation Prospects Message from the President & CEO*3 Projects in Phase II or later clinical development studiescompletely overlooked by society. As lifestyles and values diversify, we will continue to respond to unmet needs and to be sensitive to each person’s desire to have a better life.Consolidated results in the fiscal year from October 2022 to September 2023 included net sales up 0.8% year on year to 96,184 million yen, operating profit down 62.1% to 6,227 million yen, ordinary profit down 53.7% to 6,967 million yen, and profit attributable to owners of parent down 51.5% to 3,866 million yen. Our performance brought consolidated sales in sight of the 100 billion yen mark.Non-consolidated sales amounted to 85.7 billion yen. We consider it a considerable achievement that our new products were able to raise sales from the previous year even amid headwinds that included revisions to National Health Insurance drug prices. Another major achievement was Maruho Hatsujyo Kogyo Industry Co., Ltd., raising sales above 10 billion yen for the first time.deliberately and actively invested to reestablish the growth trajectory for our businesses. We use core operating profit as an important indicator because it is a fundamental source of growth in the medium- to long-term.product lines. During the plan’s three years, we obtained approval nine products.*2 We also advanced nine new projects to or beyond the development phase, which is another key performance indicator.*3 We believe this strengthened late-stage development pipeline positions us for accelerated growth even in a challenging environment.*1 Operating profit before deducting R&D expenses*2 Zebiax Oily Cream, Comclo Shampoo,† Rozex Gel,† Rapifort Wipes, DermaQuick tinea unguium, Mitchga Syringes, DermaQuick HSV, Amenalief,† Renail Gel, BEPIO Lotion († additional indication)Net sales (Millions of yen)Core operating profit*1 declined from the previous year but was in line with our expectations as we During the three years of the Fourth Medium-Term Plan, we achieved solid results and put smiles on the faces of many patients. In the fiscal year ended September 2023, we achieved sales of 96.1 billion yen, and for all fiscal years of the plan, we achieved a core operating income of 30% or more. This performance will prove extremely important to our future as it has provided funds for the investment that will lead to our growth in the future.Another achievement that sets us up for the future is the expansion of our lineup of our main 85,20985,20912.510,63110,6312018Operating profit (Millions of yen)Ratio of operating profit to net sales (%)Summary of business results for the fiscal year ended September 2023and review of the Fourth Medium-Term Plan6.56,2276,227Solid results leading into a new stage